The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 07, 2008
Filed:
Jun. 28, 2001
Gordon Freeman, Brookline, MA (US);
Irene Chernova, Brighton, MA (US);
Tatyana Chernova, Mobile, AL (US);
Nelly Malenkovich, Boston, MA (US);
Clive Wood, Boston, MA (US);
Yvette Latchman, Brookline, MA (US);
Arlene H. Sharpe, Brookline, MA (US);
Gordon Freeman, Brookline, MA (US);
Irene Chernova, Brighton, MA (US);
Tatyana Chernova, Mobile, AL (US);
Nelly Malenkovich, Boston, MA (US);
Clive Wood, Boston, MA (US);
Yvette Latchman, Brookline, MA (US);
Arlene H. Sharpe, Brookline, MA (US);
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Genetics Institute, LLC, Cambridge, MA (US);
Brigham and Women's Hospital, Boston, MA (US);
Abstract
The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. The invention further provides methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1-mediated signal. Diagnostic and treatment methods utilizing compositions of the invention are also provided.